EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Transforming Growth Factor‐β1 as a Biomarker of Malignant Behavior and PD ‐ L1 Expression in Thymic Epithelial Tumors

Chiaki Nakazono iD, Satoru Okada iD, So Tando, Shunta Ishihara, Masanori Shimomura, Tatsuo Furuya iD, Kenji Kameyama, Stefan Küffer, Denise Müller, Alexander Marx, Satoshi Teramukai, Philipp Ströbel und 2 weitere

Cancer Science · 2026

DOI: 10.1111/cas.70243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Chiaki Nakazono und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, Department of Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Thymus Neoplasms, B7-H1 Antigen, Transforming Growth Factor beta1, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Uehara Memorial Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical significance and molecular mechanisms underlying tumor progression in thymic epithelial tumors (TETs) remain largely unclear. In this retrospective single‐center study, we evaluated the prognostic value of transforming growth factor‐beta 1 (TGF‐β1) and its relationship with programmed death‐ligand 1 (PD‐L1) expression. A total of 92 patients with surgically resected TETs, including 79 thymomas and 13 thymic carcinomas, were included. Immunohistochemical analyses were performed to assess the expression of TGF‐β1, PD‐L1, phosphorylated Smad2 (pSmad2), and pSmad3. Associations between TGF‐β1 expression and clinicopathological features were analyzed, and mechanistic interactions were investigated using two thymic carcinoma cell lines exposed to exogenous TGF‐β1. High TGF‐β1 expression was observed in 28% of patients and was significantly associated with advanced Masaoka stage (III/IV), shorter tumor doubling time (median 328 vs. 713 days, p = 0.042), and lower 5‐year freedom from recurrence (FFR) rates (58.1% vs. 95.1%, p < 0.001, log‐rank test). Coexpression of high TGF‐β1 and PD‐L1 was linked to the poorest prognosis (5‐year FFR: 46.1%) and was identified as an independent predictor of recurrence (adjusted hazard ratio: 7.15; 95% confidence interval: 1.20–42.8). Immunohistochemically, TGF‐β1 expression positively correlated with PD‐L1 and pSmad2/3 expression. In vitro, TGF‐β1 stimulation upregulated PD‐L1 expression in a dose‐dependent manner, accompanied by increased pSmad2/3 activation. These findings indicate that high TGF‐β1 expression demarcates a biologically aggressive TET phenotype and, together with PD‐L1, refines postoperative risk stratification, while its ability to drive PD‐L1 via Smad signaling could support the blockade of these pathways as a potential therapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thymus NeoplasmsB7-H1 AntigenTransforming Growth Factor beta1Biomarkers, TumorNeoplasms, Glandular and EpithelialHumansMaleFemaleMiddle AgedAgedPrognosisAdultRetrospective StudiesSmad2 ProteinCell Line, TumorSmad3 ProteinThymomaAged, 80 and over

Stichwörter der Autor:innen

Smad pathwayprognostic factorprogrammed cell death‐ligand‐1thymic epithelial tumortransforming growth factor β

Substanzen

B7-H1 AntigenTransforming Growth Factor beta1Biomarkers, TumorCD274 protein, humanSmad2 ProteinTGFB1 protein, humanSMAD2 protein, humanSmad3 ProteinSMAD3 protein, human

Autor:innen und Institutionen

  • Division of Thoracic Surgery, Department of Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany.
  • Department of Pathology and Applied Neurobiology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.
  • Department of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

ORCID-Profile: Chiaki Nakazono, Satoru Okada, Tatsuo Furuya

Förderung

  • Uehara Memorial Foundation

Zitieren

APA

Nakazono, C., Okada, S., Tando, S., Ishihara, S., Shimomura, M., Furuya, T., Kameyama, K., Küffer, S., Müller, D., Marx, A., Teramukai, S., Ströbel, P., Itoh, K., & Inoue, M. (2026). Transforming Growth Factor‐β1 as a Biomarker of Malignant Behavior and PD ‐ L1 Expression in Thymic Epithelial Tumors. Cancer Science. https://doi.org/10.1111/cas.70243

Vancouver

Nakazono C, Okada S, Tando S, Ishihara S, Shimomura M, Furuya T, et al. Transforming Growth Factor‐β1 as a Biomarker of Malignant Behavior and PD ‐ L1 Expression in Thymic Epithelial Tumors. Cancer Science. 2026. doi:10.1111/cas.70243

BibTeX
@article{Nakazono2026,
  author = {Nakazono, Chiaki and Okada, Satoru and Tando, So and Ishihara, Shunta and Shimomura, Masanori and Furuya, Tatsuo and Kameyama, Kenji and Küffer, Stefan and Müller, Denise and Marx, Alexander and Teramukai, Satoshi and Ströbel, Philipp and Itoh, Kyoko and Inoue, Masayoshi},
  title = {Transforming Growth Factor‐β1 as a Biomarker of Malignant Behavior and PD ‐ L1 Expression in Thymic Epithelial Tumors},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70243}
}
Kostenlos starten →